[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559885":3},{"organization":4,"outcomesModule":7,"designInfo":53,"detailedDescription":65,"studyPopulation":52,"armGroups":66,"interventions":79,"overallOfficials":89,"centralContacts":93,"locations":102,"responsibleParty":119,"collaborators":121,"id":131,"slug":52,"hasResults":132,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":52,"eligibilityCriteria":135,"healthyVolunteers":132,"sex":136,"minAge":137,"maxAge":52,"enrollmentInfo":138,"targetDuration":52,"studyType":141,"phases":142,"briefSummary":144,"conditions":145,"keywords":52,"overallStatus":104,"whyStopped":52,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":158},{"fullName":5,"class":6},"The Second Affiliated Hospital of Chongqing Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":52},[9,13],{"measure":10,"description":11,"timeFrame":12},"Area under the movement-evoked pain intensity-time curve","Area under the pain intensity-time curve in the movement (or coughing) state within 72h after the intervention.","from 0-72 hours after the intervention",{"measure":14,"description":15,"timeFrame":16},"The incidence of chronic postoperative pain","The incidence of chronic postoperative pain at 90 days","postoperative day (POD) 90",[18,21,25,29,32,35,37,41,45,48],{"measure":19,"description":20,"timeFrame":12},"Area under the rest pain intensity-time curve","Area under the pain intensity-time curve at rest within 72h after the intervention.",{"measure":22,"description":23,"timeFrame":24},"Movement-evoked pain score","Use pain Numeric Rating Scale(NRS) to evaluate the movement-evoked pain score at 30minutes after recovery from anesthesia and at 6 hours, 12hours, 24hours , 48hours and 72 hours after the intervention.(NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)","30 minutes after recovery from anesthesia,6 hours, 12hours, 24hours , 48hours and 72 hours after the intervention",{"measure":26,"description":27,"timeFrame":28},"Pain score at rest","Use pain Numeric Rating Scale(NRS) to evaluate the pain score at rest at 30minutes after recovery from anesthesia and at 6 hours, 12hours, 24hours , 48hours and 72 hours after the intervention.(NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)","30 minutes after recovery from anesthesia,6 hours,12hours, 24hours , 48hours and 72 hours after the intervention",{"measure":30,"description":31,"timeFrame":12},"Proportion of participants who did not use rescue analgesia","Proportion of participants who did not use rescue analgesia during 0-12 hours, 12-24 hours, 24-48 hours, 48-72 hours and 0-72 hours after the intervention.",{"measure":33,"description":34,"timeFrame":12},"The cumulative dosage of rescue analgesia","The cumulative dosage of rescue analgesia during 0-12 hours, 12-24 hours, 24-48 hours, 48-72hours and 0-72hours after the intervention.",{"measure":36,"description":36,"timeFrame":12},"The time of first use of rescue analgesia",{"measure":38,"description":39,"timeFrame":40},"First time out-of-bed","Time of participant's first out-of-bed activity after surgery","From date of surgery until the date of first out-of-bed，assessed up to 7 days",{"measure":42,"description":43,"timeFrame":44},"Length of hospital stay","Duration of participants from hospital admission to hospital discharge","From date of surgery until the date of first hospital discharge，assessed up to 1 months",{"measure":46,"description":47,"timeFrame":16},"Chronic pain score","Use pain Numeric Rating Scale(NRS) to evaluate the movement-evoked pain score and rest pain score at 90 days after surgery.(NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)",{"measure":49,"description":50,"timeFrame":51},"Score of satisfaction with analgesia","At 72 hours after the intervention,the participants rated the satisfaction with analgesia.Satisfaction rating scale 0-5,where 0 was poor drug effectiveness, and 5 was excellent drug efficacy)","At 72 hours after the intervention",null,{"allocation":54,"interventionModel":55,"interventionModelDescription":56,"primaryPurpose":57,"observationalModel":52,"timePerspective":52,"maskingInfo":58},"RANDOMIZED","PARALLEL","Randomization was performed in a 1:1 ratio with the use of block randomization.SAS software (version 9.4 or higher) was used to generate the random number and the treatment group to which the random number was assigned.Assignment of Randomization Numbers Using the Interactive Web Response System (IWRS).","TREATMENT",{"masking":59,"maskingDescription":52,"whoMasked":60},"QUADRUPLE",[61,62,63,64],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","Researchers will compare liposomal bupivacaine to bupivacaine to see if liposomal bupivacaine works better to treat acute and chronic pain after video-assisted thoracoscopic lobectomy.Participants will:1.Received liposomal bupivacaine or bupivacaine paravertebral block before surgery. 2.Keep a diary of their pain scores within 30min after recovery from anesthesia and 6h, 12h, 24h, 48h, 72h and 90d after the beginning of injection of experimental drugs.",[67,73],{"label":68,"type":69,"description":70,"interventionNames":71},"intervention (liposomal bupivacaine）","EXPERIMENTAL","Participants randomized to the intervention arm received liposomal bupivacaine for paravertebral block before surgery.",[72],"Drug: Liposomal bupivacaine",{"label":74,"type":75,"description":76,"interventionNames":77},"control (bupivacaine hydrochloride)","ACTIVE_COMPARATOR","Participants randomized to the intervention arm received bupivacaine hydrochloride for paravertebral block before surgery.",[78],"Drug: Bupivacaine Hydrochloride",[80,85],{"type":81,"name":82,"description":83,"armGroupLabels":84,"otherNames":52},"DRUG","Liposomal bupivacaine","Participants randomized to the intervention arm received 266 mg of liposomal bupivacaine for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline).",[68],{"type":81,"name":86,"description":87,"armGroupLabels":88,"otherNames":52},"Bupivacaine Hydrochloride","Participants randomized to the intervention arm received 0.5% 100 mg of bupivacaine hydrochloride for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline)",[74],[90],{"name":91,"affiliation":5,"role":92},"He Huang, ph.D","STUDY_CHAIR",[94,98],{"name":91,"role":95,"phone":96,"phoneExt":52,"email":97},"CONTACT","86+13708385559","huanghe@cqmu.edu.cn",{"name":99,"role":95,"phone":100,"phoneExt":52,"email":101},"Guangyou Duan, ph.D","86+18323376014","duangy@hospital.cqmu.edu.cn",[103],{"facility":5,"status":104,"city":105,"state":106,"zip":107,"country":108,"countryCode":109,"cosmosGeoPoint":110,"geoPoint":115,"contacts":116},"RECRUITING","Chongqing","Chongqing Municipality","4000000","China","CN",{"type":111,"coordinates":112},"Point",[113,114],106.55771,29.56026,{"lat":114,"lon":113},[117],{"name":91,"role":95,"phone":118,"phoneExt":52,"email":97},"0086-13708385559",{"type":120,"investigatorFullName":52,"investigatorTitle":52,"investigatorAffiliation":52,"oldNameTitle":52,"oldOrganization":52},"SPONSOR",[122,124,126,128],{"name":123,"class":6},"People's Hospital of Chongqing",{"name":125,"class":6},"LanZhou University",{"name":127,"class":6},"Xiangya Hospital of Central South University",{"name":129,"class":130},"Shapingba District People's Hospital of Chongqing","UNKNOWN","100559885",false,"NCT06569953","Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial","Inclusion Criteria:\n\n* Participants who scheduled for elective video-assisted thoracoscopic lobectomy under general anesthesia.\n* Participants were 18 years or older.\n* 18 kg\u002Fm2≤BMI≤30 kg\u002Fm2\n* Participants with American Society of Anesthesiology (ASA) physical status I-III.\n* Understand the significance, possible benefits, potential risks of the trial in detail.Understand the procedures and methods of this study.Willing to complete the trial in strict compliance with the clinical trial protocol.Sign the informed consent form voluntarily.\n\nExclusion Criteria:\n\n* with severe cardiovascular and cerebrovascular diseases such as myocardial infarction,unstable angina pectoris,severe cardiac rhythm disorders (second- and third-degree heart block,etc.), New York Heart Association (NYHA) functional class III\u002FIV,Ischemic stroke.\n* with psychiatric disorders (such as schizophrenia,depression,etc.) and cognitive impairment.\n* with sensory disorders such as hyperalgesia.\n* with other bodily pain.\n* allergy to amide-type local anesthetics or any of the trial drugs\n* taking drugs that affect liver metabolism,corticosteroids,benzodiazepines,non-steroidal anti-inflammatory drugs(NSAIDs),opioid agonist-antagonist,central-alpha 2-agonists,anticonvulsants,antidepressants within 72h.\n* with a history of alcohol or opioid abuse.\n* who were pregnant or lactating.\n* who were currently included in another clinical study within 3 months.","ALL","18 Years",{"count":139,"type":140},284,"ESTIMATED","INTERVENTIONAL",[143],"PHASE4","The goal of this clinical trial is to evaluate the efficacy and safety of liposomal Bupivacaine administered by paravertebral block for the treatment of acute and chronic pain after video-assisted thoracoscopic lobectomy.",[146,147,148],"Acute Pain","Chronic Pain","Postoperative Pain","2025-06-24",{"date":151,"type":152},"2025-06-27","ACTUAL",{"date":154,"type":152},"2024-08-26",{"date":156,"type":140},"2025-08-31",{"name":5,"class":6},1]